Given these constructive comments, we would thus like to invite you to revise your manuscript for Life Science Alliance.
To upload the revised version of your manuscript, please log in to your account: https://lsa.msubmit.net/cgi-bin/main.plex You will be guided to complete the submission of your revised manuscript and to fill in all necessary information. Please get in touch in case you do not know or remember your login name.
We would be happy to discuss the individual revision points further with you should this be helpful.
While you are revising your manuscript, please also attend to the below editorial points to help expedite the publication of your manuscript. Please direct any editorial questions to the journal office.
The typical timeframe for revisions is three months. Please note that papers are generally considered through only one revision cycle, so strong support from the referees on the revised version is needed for acceptance.
When submitting the revision, please include a letter addressing the reviewers' comments point by point.
We hope that the comments below will prove constructive as your work progresses.
Thank you for this interesting contribution to Life Science Alliance. We are looking forward to receiving your revised manuscript.
Sincerely, Andrea Leibfried, PhD Executive Editor Life Science Alliance Meyerhofstr. 1 69117 Heidelberg, Germany t +49 6221 8891 502 e a.leibfried@life-science-alliance.org www.life-science-alliance.org
---------------------------------------------------------------------------

A. THESE ITEMS ARE REQUIRED FOR REVISIONS
--A letter addressing the reviewers' comments point by point.
--An editable version of the final text (.DOC or .DOCX) is needed for copyediting (no PDFs).
--High-resolution figure, supplementary figure and video files uploaded as individual files: See our detailed guidelines for preparing your production-ready images, http://www.life-sciencealliance.org/authors --Summary blurb (enter in submission system): A short text summarizing in a single sentence the study (max. 200 characters including spaces). This text is used in conjunction with the titles of papers, hence should be informative and complementary to the title and running title. It should describe the context and significance of the findings for a general readership; it should be written in the present tense and refer to the work in the third person. Author names should not be mentioned.
B. MANUSCRIPT ORGANIZATION AND FORMATTING:
Full guidelines are available on our Instructions for Authors page, http://www.life-sciencealliance.org/authors We encourage our authors to provide original source data, particularly uncropped/-processed electrophoretic blots and spreadsheets for the main figures of the manuscript. If you would like to add source data, we would welcome one PDF/Excel-file per figure for this information. These files will be linked online as supplementary "Source Data" files. ***IMPORTANT: It is Life Science Alliance policy that if requested, original data images must be made available. Failure to provide original images upon request will result in unavoidable delays in publication. Please ensure that you have access to all original microscopy and blot data images before submitting your revision.***
Reviewer #1 (Comments to the Authors (Required)):
In their manuscript, the authors describe the ultrastructure of Babesia microti in the red blood cell. They observe a membraneous network budding off from the parasite. While the paper seems straightforward there are quite a number of inconsistencies that need to be addressed prior to publication:
The authors need to compare EM level data from B. microti with data from at least two other Babesia parasites. Even by Giemsa staining it is very obvious that B. microti has a different intracellular appearance as most other Babesia species. This needs to be clearly and upfront communicated. The reported observation could also be just stretching events as seen in P. falciparum ring stages. This should be discussed. The BmGPI12 staining with confocal needs another control antibody to convince this reviewer.
Other points: Figure 6B needs legend, how does export work? Figure S1 misses 'S' in second panel Authors need to mention that 3D EM would be beneficial to look at whole cell, e.g. FIB SEM or serial sections to investigate whether the vesicles are truly disconnected from the parasite body. Page 4, there are more than 3 species causing disease in humans. Page 12: the protein is NOT found in the plasma fraction according to Figure S2 The manuscript is interesting to explore how the antigen of Babesia microti is being transported to RBC membrane. However, I have some concerns in the manuscript as follows.
1. Two strains of B. microti were used in the present study. Furthermore, several knockout mice were used for maintaining of strains. However, I could find the reasons why two strains and knockout mice were necessary. Were there some differences in the development of parasitemia between immunocompetent and knockout mice, and results between two strains, respectively? The authors should add the information on these questions. 2. For the determination of parasitemia, the sentence must be mixed up with some other method (p.6, lines 10-14). 3. There was no data for "TER-119 was not identified in the plasma (p. 12, line 15) in Fig, 1B .". 4. The authors described that BmIPA48 was found inside of vesicles (p.15, line 11). However, some gold particles were found mainly outside of IV indicated by arrow in the upper left of Fig.5E . 5. Maltese cross (Tetrad form) is a morphologic characteristic of B. microti and it appears in the early stage (less than 50% of whole parasitized RBC) before peak parasites and disappears in the later stage of developmental course of parasitemia in BALB-c mice (Infection and Immunity, 71:411-417, 2003) . Although tetrad forms and tetrad forms with IOV were seldom found in the present study ( Fig. 2C) , the model of antigen export was suggested for tetrad form only in Fig. 6 Thekkianiath et al present remarkable data suggesting novel mechanism of protein transport used by the intracellular parasite, Babesia microti. This parasite resides within the RBC but is not contained inside a vacuole. Its genome lacks homologs of the translocon machinery used for protein export by Plasmodium falciparum, a related Apicomplexan that also parasitizes RBCs but one that resides within a vacuole. The authors demonstrate, primarily through EM, that intracellular B. microti stages form a network of long tubes of incipient vesicles, termed ToV, that extrude from the parasite plasma membrane. Infected RBCs also contain vesicles containing parasite proteins. At least, two secreted proteins of B. microti, BP112 and IPA48, that elicit strong host antibody responses, are present in these ToVs and vesicles. Their immunolocalization is supported by cellfractionation experiments. Localization of BP112 and IPA48 to ToV suggests that these structures are part of the parasite-encoded machinery for trafficking proteins to the host cell cytoplasm for eventual secretion. The EM data is compelling and supportive of the paper's conclusions. One minor weakness that can be addressed in the Discussion section, is the relevance of the observation that IPA48 is not detected in the vesicle-free fraction. In this reviewer's opinion, this could result from lower sensitivity of the anti-IPA48 antibody compared to the anti-GP112 antibody or the higher overall abundance of GP112. Additional comments below are meant as suggestions to the authors.
1) It would be useful to test if ToV and vesicles were selective in their cargo. For example, testing the presence in ToVs or vesicle of parasite cytoplasmic proteins. If ToVs and vesicles serve in polar transport of secreted proteins, then parasite cytoplasmic proteins would be expected to be excluded from these structures. Furthermore, such "selection of proteins" could imply that B. microti uses a novel signal to mark proteins destined for secretion. On the other hand, if ToVs and vesicles bud of from the parasite plasma membrane in a more indiscriminate fashion, then they may contain both proteins destined for secretion and ones meant to be cytoplasmic. 2) Is there any evidence for ToV merging with the RBC PM? It would be intriguing if the ToV directly deliver proteins to the RBC surface. What is the relationship between Bgp112-containing ToVs in Fig 4B and 4 E-F. Are the vesicles and tubes in Fig 4E-F thought to arise from the ToVs seen in Fig  4B? 3) Is ToV formation associated with a specific parasite stage? While this seems to be the motivation behind Fig 2C, Reviewer #1 (Comments to the Authors (Required)):
Major comments
The authors need to compare EM level data from B. microti with data from at least two other Babesia parasites. Even by Giemsa staining it is very obvious that B. microti has a different intracellular appearance as most other Babesia species. This needs to be clearly and upfront communicated. The reported observation could also be just stretching events as seen in P. falciparum ring stages. This should be discussed.
Response:
We thank the reviewer for the suggestions. We provide Giemsa-stained smears from B. duncani, which has been recently successfully cultured in human RBCs (Abraham et al., JBC 2018). The filamentous forms that we see in B. microti are also present in B. duncani during its intraerythrocytic development as well as after cell division as links between daughter parasites ( Figure S3 ). We do not maintain Babesia parasites other than B. microti and B. duncani and therefore we can't possibly determine whether the filamentous forms are found in every Babesia species in nature. However, a search of available Giesma-stained blood smears from other Baebsia species in the published literature revealed the presence of similar structures. We refer to these publications in the revised manuscript.
The BmGPI12 staining with confocal needs another control antibody to convince this reviewer.
We now provide supplemental images of BmGPI12-labeling by confocal microscopy using three peptide polyclonal (3 separate antibodies) and one monoclonal antibodies against BmGPI12. Data using these different antibodies are provided as supplemental figures (Fig. S2) . The data with these antibodies reveal the same features reported in Fig. 1 with the polyclonal antibodies against the polypeptide (1-302).
Other points: Figure 1 , Figure S1A and Figure 5A look like different exposures of the same blot. The authors should supply a similar exposed version of the different blots to diffuse possible concerns.
We thank the reviewer for noticing this error, which occurred as a result of selecting which figures to be in the main paper and which figures to move to the supplementary files. We have now updated the manuscript and corrected the issue in Figure 1 . In addition, we show the data for both B. microti strains LabS1 and PRA99. Authors need to mention that 3D EM would be beneficial to look at whole cell, e.g. FIB SEM or serial sections to investigate whether the vesicles are truly disconnected from the parasite body.
Thank you very much for the suggestion. We included a statement in the discussion to thay effect.
Page 4, there are more than 3 species causing disease in humans.
We have updated the manuscript and provide a reference to a recent review stating the presence of more species that infect humans (Krause. 2019).
Page 12, the protein is NOT found in the plasma fraction according to Figure S2 . Please clarify. The labelling of the blots is not ideal.
BmRON2 most likely undergoes proteolytic degradation upon release of daughter parasites following rupture of the infected cell and we see the cleaved products in the parasite membrane fractions. A new Western blot has been included to show the presence of the full length protein and degradation products in the P and S (plasma) fractions. Degradation of BmRON2 has also been reported by Ord and colleagues (reference included in the revised manuscript).
Page 12: the Ord paper does not mention what it is referred at.
Ord et al. 2016 identified and characterized BmRON2 in parasite extracts. We referenced this publication in our manuscript as their results (BmRon2 profile in the parasite fraction) are similar to ours.
Page 14: what do the authors mean by 'erythrocyte environment'?
Response: this is basically the blood in mouse but since we are analyzing the plasma fraction, we refer to this environment as plasma throughout the manuscript.
Page 17: short term culture is not described in the methods
Response:
Since we do not include data from short-term culture of B. microti, this sentence has been removed.
Page 18: maybe a concluding sentence or two at end of discussion?
Response: A concluding sentence at the end of discussion has now been added.
Reviewer #2 (Comments to the Authors (Required)):
The manuscript is interesting to explore how the antigen of Babesia microti is being transported to RBC membrane. However, I have some concerns in the manuscript as follows.
1. Two strains of B. microti were used in the present study. Furthermore, several knockout mice were used for maintaining of strains. However, I could find the reasons why two strains and knockout mice were necessary. Were there some differences in the development of parasitemia between immunocompetent and knockout mice, and results between two strains, respectively? The authors should add the information on these questions.
Response: For regular maintenance of B. microti strains we use both rag2D and scid mice upon availability. Parasite development in these immunocompromised mice is the same with parasitemia increasing over time and remaining around ~50% for several weeks.
2. For the determination of parasitemia, the sentence must be mixed up with some other method (p.6, lines 10-14).
Response: Thank you very much for pointing this out to us. In the revised manuscript, we have corrected this issue.
3. There was no data for "TER-119 was not identified in the plasma (p. 12, line 15) in Fig, 1B .".
Response: Thank you very much for pointing this out. We corrected the typographical error to Fig. 1A .
4. The authors described that BmIPA48 was found inside of vesicles (p.15, line 11). However, some gold particles were found mainly outside of IV indicated by arrow in the upper left of Fig.5E .
Response: Thank you very much for pointing this out. The majority of gold particles appeared within vesicles (of the 8 vesicles in panel D, four have more than 4 gold particle, three have 3 gold particles and one has 2 gold particles). Gold particles that are outside are due to the fact that some of the vesicles are just below the focal plane in the section (outline of vesicles can be seen in the erythrocyte cytoplasm). The antibody most likely recognized the specific epitope although the vesicle as such is not visible in the section.
Maltese cross (Tetrad form)
is a morphologic characteristic of B. microti and it appears in the early stage (less than 50% of whole parasitized RBC) before peak parasites and disappears in the later stage of developmental course of parasitemia in BALB-c mice (Infection and Immunity, 71:411-417, 2003) . Although tetrad forms and tetrad forms with IOV were seldom found in the present study (Fig. 2C) , the model of antigen export was suggested for tetrad form only in Fig. 6 Reviewer #3 (Comments to the Authors (Required)):
Thekkianiath et al present remarkable data suggesting novel mechanism of protein transport used by the intracellular parasite, Babesia microti. This parasite resides within the RBC but is not contained inside a vacuole. Its genome lacks homologs of the translocon machinery used for protein export by Plasmodium falciparum, a related Apicomplexan that also parasitizes RBCs but one that resides within a vacuole. The authors demonstrate, primarily through EM, that intracellular B. microti stages form a network of long tubes of incipient vesicles, termed ToV, that extrude from the parasite plasma membrane. Infected RBCs also contain vesicles containing parasite proteins. At least, two secreted proteins of B. microti, BP112 and IPA48, that elicit strong host antibody responses, are present in these ToVs and vesicles. Their immunolocalization is supported by cell-fractionation experiments. Localization of BP112 and IPA48 to ToV suggests that these structures are part of the parasite-encoded machinery for trafficking proteins to the host cell cytoplasm for eventual secretion. The EM data is compelling and supportive of the paper's conclusions.
One minor weakness that can be addressed in the Discussion section, is the relevance of the observation that IPA48 is not detected in the vesicle-free fraction. In this reviewer's opinion, this could result from lower sensitivity of the anti-IPA48 antibody compared to the anti-GP112 antibody or the higher overall abundance of GP112. Additional comments below are meant as suggestions to the authors.
1) It would be useful to test if ToV and vesicles were selective in their cargo. For example, testing the presence in ToVs or vesicle of parasite cytoplasmic proteins. If ToVs and vesicles serve in polar transport of secreted proteins, then parasite cytoplasmic proteins would be expected to be excluded from these structures. Furthermore, such "selection of proteins" could imply that B. microti uses a novel signal to mark proteins destined for secretion. On the other hand, if ToVs and vesicles bud of from the parasite plasma membrane in a more indiscriminate fashion, then they may contain both proteins destined for secretion and ones meant to be cytoplasmic.
Response:
Thank you very much for the suggestion. Testing if the TOVs and the vesicles are selective in their cargo is interesting to investigate in future studies. At this time, no antibodies against specific cargo molecules are available and such studies cannot be conducted at this time.
2) Is there any evidence for ToV merging with the RBC PM? It would be intriguing if the ToV directly deliver proteins to the RBC surface. What is the relationship between Bgp112-containing ToVs in Fig 4B and 4 E-F. Are the vesicles and tubes in Fig 4E- F thought to arise from the ToVs seen in Fig 4B? Response: Thank you very much for the question. Based on our results, we have not seen any evidence for TOV merging with the plasma membrane of red blood cells. Based on the method used to isolate vesicles, we believe that those vesicles seen in 4E and 4F represent the same IV and TOVs seen in 4B.
3) Is ToV formation associated with a specific parasite stage? While this seems to be the motivation behind Fig. 2C , the conclusion is not clearly stated.
Thank you very much for the question. Based on the Giemsa-stained smear results, we do not see any relationship between development stages and TOV formation. In the revised manuscript, we included this information. Thank you for submitting your revised manuscript entitled "Evidence for vesicle-mediated antigen export by the human pathogen Babesia microti". Your work was re-assessed by original reviewer #1 and given this reviewer's input, we would be happy to publish your paper in Life Science Alliance pending final revisions:
-please address the remaining concerns of reviewer #1 by further discussion/changing the discussion and adding further context from the existing literature -please upload the supplementary figures as individual files; these will be displayed in-line in the HTML version of your paper, so please provide them as single page files (figure S2 currently spans over two pages) -please link your profile in our submission system to your ORCID iD, you should have received an email with instructions on how to do so If you are planning a press release on your work, please inform us immediately to allow informing our production team and scheduling a release date.
To upload the final version of your manuscript, please log in to your account: https://lsa.msubmit.net/cgi-bin/main.plex You will be guided to complete the submission of your revised manuscript and to fill in all necessary information. Please get in touch in case you do not know or remember your login name.
To avoid unnecessary delays in the acceptance and publication of your paper, please read the following information carefully.
A. FINAL FILES:
These items are required for acceptance.
--High-resolution figure, supplementary figure and video files uploaded as individual files: See our detailed guidelines for preparing your production-ready images, http://www.life-sciencealliance.org/authors --Summary blurb (enter in submission system): A short text summarizing in a single sentence the study (max. 200 characters including spaces). This text is used in conjunction with the titles of papers, hence should be informative and complementary to the title. It should describe the context and significance of the findings for a general readership; it should be written in the present tense and refer to the work in the third person. Author names should not be mentioned.
B. MANUSCRIPT ORGANIZATION AND FORMATTING:
Full guidelines are available on our Instructions for Authors page, http://www.life-sciencealliance.org/authors We encourage our authors to provide original source data, particularly uncropped/-processed electrophoretic blots and spreadsheets for the main figures of the manuscript. If you would like to add source data, we would welcome one PDF/Excel-file per figure for this information. These files will be linked online as supplementary "Source Data" files. **Submission of a paper that does not conform to Life Science Alliance guidelines will delay the acceptance of your manuscript.** **It is Life Science Alliance policy that if requested, original data images must be made available to the editors. Failure to provide original images upon request will result in unavoidable delays in publication. Please ensure that you have access to all original data images prior to final submission.** **The license to publish form must be signed before your manuscript can be sent to production. A link to the electronic license to publish form will be sent to the corresponding author only. Please take a moment to check your funder requirements.** **Reviews, decision letters, and point-by-point responses associated with peer-review at Life Science Alliance will be published online, alongside the manuscript. If you do want to opt out of this transparent process, please let us know immediately.** Thank you for your attention to these final processing requirements. Please revise and format the manuscript and upload materials within 7 days.
Thank you for this interesting contribution, we look forward to publishing your paper in Life Science Alliance.
